Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Julie Mount"'
Autor:
David Kernick, Nazanin Kondori, Andrew Pain, Julie Mount, Camilla Appel, Michael Ranopa, Tania Gulati
Publikováno v:
BMC Primary Care, Vol 25, Iss 1, Pp 1-9 (2024)
Abstract Background Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are recommended by the United Kingdom National Institute of Health and Care Excellence for the prevention of migraine as treatment beyond third line. We report migr
Externí odkaz:
https://doaj.org/article/50f6538c556a42319c3775ab1ec7e029
Publikováno v:
BMC Rheumatology, Vol 4, Iss 1, Pp 1-10 (2020)
Abstract Background Many patients with rheumatoid arthritis (RA) do not attain remission/low disease activity, remaining in a moderate disease activity state (MDAS) with ongoing disability and impaired quality of life (QoL). If patients in persistent
Externí odkaz:
https://doaj.org/article/d0d3572fb81f4a49beadbd9c32f08ef7
Autor:
Simon de Lusignan, William Hinton, Emmanouela Konstantara, Neil Munro, Martin Whyte, Julie Mount, Michael Feher
Publikováno v:
BMC Health Services Research, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background In the UK, type 2 diabetes mellitus (T2D) is largely managed in primary care. Delay in the intensification to injectable therapy, a form of clinical inertia, is associated with worse glycaemic control. UK general practice is highl
Externí odkaz:
https://doaj.org/article/edfa4efd6cc847bcab367f5fd3e0d9ed
Autor:
Martin B Whyte, William Hinton, Andrew McGovern, Jeremy van Vlymen, Filipa Ferreira, Silvio Calderara, Julie Mount, Neil Munro, Simon de Lusignan
Publikováno v:
PLoS Medicine, Vol 16, Iss 10, p e1002942 (2019)
BackgroundDisparities in type 2 diabetes (T2D) care provision and clinical outcomes have been reported in the last 2 decades in the UK. Since then, a number of initiatives have attempted to address this imbalance. The aim was to evaluate contemporary
Externí odkaz:
https://doaj.org/article/214d590eae1b48d8a8de610716748f36
Autor:
Simon de Lusignan, Andrew McGovern, William Hinton, Martin Whyte, Neil Munro, Emily D. Williams, Afrodita Marcu, John Williams, Filipa Ferreira, Julie Mount, Manasa Tripathy, Emmanouela Konstantara, Benjamin C. T. Field, Michael Feher
Publikováno v:
Diabetes Therapy. 13:1789-1809
Initiation of injectable therapies in type 2 diabetes (T2D) is often delayed, however the reasons why are not fully understood.A mixed methods study performed in sequential phases. Phase 1: focus groups with people with T2D (injectable naïve [n = 12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a967d6f4e83e059439e25d67941ea51
https://doi.org/10.1007/s13300-022-01306-z
https://doi.org/10.1007/s13300-022-01306-z
Autor:
Julie Mount, Kristina Boye, Nora Hennies, Sven Görgens, Celina Gollop, Justin Chen, Mitch DeKoven, Victoria Divino
Publikováno v:
Diabetologie und Stoffwechsel.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf778659552155c87b412b52619ac0d6
https://doi.org/10.1055/s-0043-1767898
https://doi.org/10.1055/s-0043-1767898
Autor:
Martin B. Whyte, Mark Joy, William Hinton, Andrew McGovern, Uy Hoang, Jeremy van Vlymen, Filipa Ferreira, Julie Mount, Neil Munro, Simon de Lusignan
Publikováno v:
Diabetes, Obesity and Metabolism. 24:1310-1318
To determine whether achieving early glycaemic control, and any subsequent glycaemic variability, was associated with any change in the risk of major adverse cardiovascular events (MACE).A retrospective cohort analysis from the Oxford-Royal College o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83dcd4d7812e0ee1d4c8b03ebc13799f
https://doi.org/10.1111/dom.14705
https://doi.org/10.1111/dom.14705
Autor:
Christopher J Edwards, Julie Mount, Alexandra Meeks, Tania Gulati, Liliana Zaremba-Pechmann, Mohamed Sheesh, Esbjörn Larsson, Elaine Dennison
Publikováno v:
Rheumatology.
ObjectivesTo describe selected baseline characteristics, continuation with baricitinib and disease activity over time in patients initiating treatment with baricitinib in a UK real-world rheumatology setting.MethodsBaseline and follow-up data were an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c90e7b5dd4fe269ab29e1f1f4bdcf59c
https://doi.org/10.1093/rheumatology/kead074
https://doi.org/10.1093/rheumatology/kead074
Autor:
Olivia Massey, Iskandar Idris, Lill-Brith von Arx, Theo Tritton, Robert Wood, Joanne Webb, Jonathan Rachman, Dionysis Spanopoulos, Julie Mount
Publikováno v:
Diabetes, Obesity and Metabolism. 24:289-295
Aims: To determine the proportion of UK patients with type 2 diabetes (T2D) who meet the cardiovascular (CV) or combined CV/core eligibility criteria of the CV outcome trials (CVOTs) of UK-marketed glucagon-like peptide-1 receptor agonists (GLP-1 RAs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15415d243b268450c0393f70823e1e58
https://doi.org/10.1111/dom.14580
https://doi.org/10.1111/dom.14580
Publikováno v:
BMC Rheumatology, Vol 4, Iss 1, Pp 1-10 (2020)
BMC Rheumatology
BMC Rheumatology
Background Many patients with rheumatoid arthritis (RA) do not attain remission/low disease activity, remaining in a moderate disease activity state (MDAS) with ongoing disability and impaired quality of life (QoL). If patients in persistent MDAS wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24fd744d807e8484725ff25605525d03
http://link.springer.com/article/10.1186/s41927-020-00161-4
http://link.springer.com/article/10.1186/s41927-020-00161-4